PRECISE Study (Ovarian Cancer) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if we can identify biomarkers that indicate the presence of ovarian cancer or indicate that it is likely to develop. Biomarkers are substances that can be released from cancer cells into the blood and can provide information on the following things: changes to someone's genes or DNA, how cancer cells will respond to cancer treatment, and whether cells are becoming resistant (no longer responding) to cancer treatment.
What is the Condition Being Studied?
Ovarian Cancer Detection and Risk Determination
Who Can Participate in the Study?
Women ages 18+ who:
- Are scheduled to have a risk-reducing salpingo-oophorectomy procedure to remove their fallopian tubes or a removal of an adnexal (ovarian or fallopian tube mass) as part of their regular clinical care
- Have never been treated with chemotherapy or pelvic radiation
- Are not pregnant or breastfeeding
For more information about who can join this study, please contact the study team at sarah.linhart@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, we will collect the following samples from you:
- Blood draws
- Tissue samples from your fallopian tubes or an identifed mass on your fallopian tube(s) if you are scheduled to have them removed
Study Details
Full Title
Assessing the predictive capability of circulating tumor
DNA (ctDNA) as a screening tool for ovarian cancer
Principal Investigator
Gynecologic Oncologist
Protocol Number
IRB:
PRO00112908
Phase
Phase
Pilot
Enrollment Status
Open for Enrollment